WA
VRTX icon

Winfield Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Winfield Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-200
Closed -$22K – 915
2017
Q1 		$22K Sell
200
-200
-50% -$17.6K 0.01% 260
2016
Q4 		$29K Hold
400
– – 0.02% 223
2016
Q3 		$35K Hold
400
– – 0.02% 204
2016
Q2 		$34K Sell
400
-350
-47% -$30.2K 0.02% 204
2016
Q1 		$60K Sell
750
-950
-56% -$85.9K 0.04% 155
2015
Q4 		$214K Buy
+1,700
New +$205K 0.14% 104

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Winfield Associates's VRTX Position: Q2 2017 in Review

Winfield Associates sold out of Vertex Pharmaceuticals (VRTX) in Q2 2017, closing a stake of 200 shares — an estimated $22K sold.

Winfield Associates first reported a position in VRTX in Q4 2015 and held it in 6 quarters. The position peaked at $214K in Q4 2015. 582 funds tracked by Wall St. Rank hold VRTX as of Q2 2017.

  • Winfield Associates reported no remaining Vertex Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Winfield Associates sold 200 Vertex Pharmaceuticals shares in Q2 2017, an estimated $22K.
  • Winfield Associates first reported a position in Vertex Pharmaceuticals in Q4 2015 and held it in 6 quarters.
  • Winfield Associates's Vertex Pharmaceuticals position peaked at $214K in Q4 2015.
  • 582 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2017.

Based on Winfield Associates's 13F filing for Q2 2017, filed 27 Jul 2017.